FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial. PMID 40694062 · Int Clin Psychopharmacol · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study. PMID 40662488 · Int Clin Psychopharmacol · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fecal Immunochemical Test Completion by Instruction Type: A Randomized Clinical Trial Comparing Quick Response Code-Linked Video to Pictorial Instructions. PMID 40622392 · Am J Gastroenterol · 2026-Mar-01 The record describes a randomized quality improvement study comparing instruction methods for fecal immunochemical test (FIT) completion in colorectal cancer screening. While oncology and human criteria are met, and it is randomized, it lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The study is also not Phase III or II/III. Thus, it does not meet all eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis. PMID 40531526 · Am J Gastroenterol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial. PMID 40384092 · Hepatology · 2026-Mar-01 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Role of Preoperative Tapentadol in Reduction of Peri-operative Analgesics Requirements After Breast Conservative Surgery in Cancer Patients: A Randomized Controlled Trial. PMID 42394994 · J Cancer Allied Spec · 2026-Mar The study is a randomized, controlled trial involving a drug in an oncology (breast cancer) population, but it is an analgesia/safety study focused on perioperative pain management, not an efficacy trial for a cancer treatment with a time-to-event endpoint. Furthermore, the trial phase is not specified, so it cannot be confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study. PMID 42370118 · EULAR Rheumatol Open · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty. PMID 42051839 · Cureus · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol. PMID 42022357 · Precis Radiat Oncol · 2026-Mar 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Analysis of depressive symptom trajectory patterns with zuranolone: Time-series clustering of Japanese Phase 2 and Phase 3 trial data. PMID 42022339 · PCN Rep · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113). PMID 41994030 · ESMO Gastrointest Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial. PMID 41938843 · EClinicalMedicine · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial. PMID 41937811 · JCO Oncol Adv · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis. PMID 41930050 · Cureus · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Diet and Physical Activity Interventions to Improve Outcomes in Colorectal Cancer Survivors: A Multicenter Randomized Controlled Trial in North Africa. PMID 41886719 · JCO Glob Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| An evaluation of cytisinicline for smoking cessation in adult smokers. PMID 41885781 · Expert Opin Pharmacother · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study). PMID 41884323 · Cureus · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival Outcomes of Concurrent Chemoradiotherapy for Postoperative High-Risk Salivary Gland Carcinomas. PMID 41878954 · Cancer Med · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer. PMID 41866301 · Psychooncology · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial. PMID 41853747 · ESMO Gastrointest Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial. PMID 41852554 · Open Forum Infect Dis · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. PMID 41852303 · Cancer Med · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis. PMID 41846682 · ERJ Open Res · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled Trial. PMID 41825129 · J Natl Compr Canc Netw · 2026-Mar The study is an eligible Phase III randomized trial with drug-containing context (chemotherapy), but it fails the time-to-event endpoint criterion. The primary outcomes are cognitive impairment and mental fatigue scores, which are continuous patient-reported outcomes, not time-to-event events (like survival or progression). No Kaplan-Meier curves, hazard ratios, or time-to-event endpoints are mentioned. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing Clinical Characteristics and Outcomes of Tenecteplase Versus Alteplase in Young Adult Patients With Stroke: A Secondary Analysis of the AcT Trial. PMID 41815318 · Stroke Vasc Interv Neurol · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Secondary cytoreductive surgery (S-CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent ovarian cancer: Current evidence and clinical perspectives. PMID 41813375 · Taiwan J Obstet Gynecol · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial. PMID 41812092 · JCO Glob Oncol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Multicentre dosimetry audit in the European randomized phase III study of neoadjuvant chemoradiotherapy using proton versus photon radiotherapy in locally advanced oesophageal cancer. PMID 41810037 · Phys Imaging Radiat Oncol · 2026-Mar The record is an abstract for a dosimetry audit (technical quality assurance) within a randomized phase III oncology trial. While the parent trial (PROTECT) is oncologic, human, randomized, and phase III, this specific abstract reports only on radiation dose measurement verification, not on any clinical efficacy endpoint (e.g., OS, PFS). Furthermore, the intervention compared is proton versus photon radiotherapy (non-drug), and the abstract does not present the primary trial results. Therefore, it is ineligible. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial. PMID 41808691 · Lancet Reg Health Southeast Asia · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Influence of Hospital and Surgeon Volumes on Clinical Outcomes After Standard Surgery for Advanced Gastric Cancer: Supplementary Analysis of the Multicenter Randomized Phase III Trial JCOG1001. PMID 41799591 · Ann Gastroenterol Surg · 2026-Mar This is a supplementary analysis of a phase III randomized trial (JCOG1001) that compares surgical techniques (standard vs. experimental surgery) for gastric cancer. The intervention is surgical, not drug-containing. Therefore, it does not meet the inclusion criterion of a drug-containing intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT. PMID 41797548 · Health Technol Assess · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Critique of phase II agents for non-small cell lung cancer: what is our clinical need and which agents have potential? PMID 41797519 · Expert Opin Investig Drugs · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor. PMID 41792865 · Clin Transl Sci · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial. PMID 41785896 · Lancet Oncol · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma. PMID 41785669 · ESMO Open · 2026-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| PRehab tO PreparE Living Liver Donors for Enhanced Recovery (PROPELLER): A Feasibility Randomized Controlled Trial. PMID 41782467 · Clin Transplant · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of vosoritide on genu varum in children with achondroplasia after 1 year in randomized placebo-controlled trials. PMID 41766933 · J Endocr Soc · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Overall Survival of Glioblastoma Patients Treated With a Combination of 7 Micronutrients: A Nutraceutical Trial. PMID 41760279 · Anticancer Res · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma. PMID 41747585 · ESMO Open · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings. PMID 41746995 · Expert Opin Investig Drugs · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pyruvate Kinase Activators for Sickle Cell Disease: An Exploratory Systematic Review and Meta-Analysis. PMID 41742605 · Hemoglobin · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| HCC recurrence in liver transplants treated with hypothermic oxygenated machine perfusion: An international matched cohort study. PMID 41737541 · JHEP Rep · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. PMID 41732008 · Future Oncol · 2026-Mar The publication is a clinical trial protocol describing the design of two randomized phase III trials (OMAHA-003 and OMAHA-004) evaluating opevesostat. It does not report results, efficacy data, or time-to-event endpoints (e.g., OS, PFS) from a completed trial. Therefore, it is excluded as it is not an original formal-result report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of nonsteroidal anti-inflammatory drugs on union, opioid utilization, and pain management for tibial fractures (NSAID Trial): a pragmatic randomized clinical trial protocol. PMID 41725885 · OTA Int · 2026-Mar 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study. PMID 41722591 · Lancet Neurol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of intensive task-specific training in people with recent spinal cord injury: a phase 3, pragmatic, randomised, assessor-blinded, superiority trial. PMID 41722590 · Lancet Neurol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab. PMID 41722015 · Oncol Ther · 2026-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Sex- and Age-Stratified Outcomes of Colonoscopy Versus Faecal Immunochemical Testing: Post-Analysis of the COLONPREV Study. PMID 41715250 · United European Gastroenterol J · 2026-Mar The study is a randomized, human, oncology trial comparing two screening methods (colonoscopy vs. FIT) for colorectal cancer mortality and incidence. However, it lacks a drug intervention and does not explicitly report time-to-event (Kaplan-Meier, HR) analyses, and it is not a Phase III trial of a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial. PMID 41714818 · Scand J Immunol · 2026-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial. PMID 41713442 · Lancet Glob Health · 2026-Mar The record describes a randomized trial of tobacco cessation interventions for people living with HIV. While it includes a pharmacotherapy arm (nicotine replacement therapy), it is not an oncology trial and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |